WO2011088126A3 - Treatment of viral infection with prenyltransferase inhibitors - Google Patents

Treatment of viral infection with prenyltransferase inhibitors Download PDF

Info

Publication number
WO2011088126A3
WO2011088126A3 PCT/US2011/020998 US2011020998W WO2011088126A3 WO 2011088126 A3 WO2011088126 A3 WO 2011088126A3 US 2011020998 W US2011020998 W US 2011020998W WO 2011088126 A3 WO2011088126 A3 WO 2011088126A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
viral infection
prenyltransferase inhibitors
inhibitors
prenyltransferase
Prior art date
Application number
PCT/US2011/020998
Other languages
French (fr)
Other versions
WO2011088126A2 (en
Inventor
David Cory
Ingrid Choong
Brian Murphy
Wenjin Yang
Jeffrey S. Glenn
Original Assignee
Eiger Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals, Inc. filed Critical Eiger Biopharmaceuticals, Inc.
Publication of WO2011088126A2 publication Critical patent/WO2011088126A2/en
Publication of WO2011088126A3 publication Critical patent/WO2011088126A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Inhibitors of prenylation such as farnesyl transferase inhibitors can be used to treat HDV infection.
PCT/US2011/020998 2010-01-13 2011-01-12 Treatment of viral infection with prenyltransferase inhibitors WO2011088126A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29479310P 2010-01-13 2010-01-13
US61/294,793 2010-01-13

Publications (2)

Publication Number Publication Date
WO2011088126A2 WO2011088126A2 (en) 2011-07-21
WO2011088126A3 true WO2011088126A3 (en) 2011-11-10

Family

ID=44304946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/020998 WO2011088126A2 (en) 2010-01-13 2011-01-12 Treatment of viral infection with prenyltransferase inhibitors

Country Status (1)

Country Link
WO (1) WO2011088126A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3620163A1 (en) * 2014-05-01 2020-03-11 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN107530338B (en) * 2015-04-21 2020-12-01 艾格尔峰生物制药有限公司 Pharmaceutical composition comprising lonafarnib and ritonavir
JP7187315B2 (en) * 2015-11-04 2022-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッド Treatment of hepatitis delta virus infection
US10953072B2 (en) 2016-02-19 2021-03-23 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection with interferon lambda
EP4032534A1 (en) * 2021-01-22 2022-07-27 Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH Lonafarnib for use in the treatment of viral infections
WO2023287620A1 (en) * 2021-07-13 2023-01-19 Michael Rabinoff Methods for treating coronavirus infection
CN117257805B (en) * 2023-11-10 2024-03-12 中山大学附属第八医院（深圳福田） Application of nucleoside reverse transcriptase inhibitor in preparation of anti-vascular calcification drugs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031641A1 (en) * 1996-02-29 1997-09-04 Duke University Method of treating hepatitis delta virus infection
US7101897B2 (en) * 1999-12-22 2006-09-05 Astrazeneca Ab Farnesyl transferase inhibitors
US7271174B2 (en) * 2003-06-25 2007-09-18 Schering Corporation Metabolites of tricyclic amides useful for inhibition of G-protein function and methods of treatment of proliferative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031641A1 (en) * 1996-02-29 1997-09-04 Duke University Method of treating hepatitis delta virus infection
US7101897B2 (en) * 1999-12-22 2006-09-05 Astrazeneca Ab Farnesyl transferase inhibitors
US7271174B2 (en) * 2003-06-25 2007-09-18 Schering Corporation Metabolites of tricyclic amides useful for inhibition of G-protein function and methods of treatment of proliferative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRUNO B. BORDIER ET AL.: "In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 112, no. 3, 2003, pages 407 - 414 *

Also Published As

Publication number Publication date
WO2011088126A2 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
WO2011088126A3 (en) Treatment of viral infection with prenyltransferase inhibitors
PH12018502234B1 (en) Treatment of cancer with tor kinase inhibitors
EP3038661A4 (en) Methods and compositions for rna-guided treatment of hiv infection
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2015DN01198A (en)
IN2014CN02887A (en)
MX356525B (en) Aav -vectors for use in gene therapy of choroideremia.
SG11201406142XA (en) Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
EA201590703A1 (en) MEK INHIBITORS FOR TREATING VIRAL DISEASES
HK1210187A1 (en) Compositions and methods related to prevention and treatment of rabies infection
PH12014501032A1 (en) 2-thiopyrimidinones
HK1202820A1 (en) Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses
PL2534150T3 (en) Methods of treating viral infection
WO2014062878A3 (en) Treatment of prostate cancer with tor kinase inhibitors
ZA201504151B (en) Use of connexin channel inhibitors to protect grafts
EP3066116A4 (en) Treatment of damaged nerve with pten inhibitor
AU2013318309A8 (en) Methods for treating hepatitis C
EP2838522A4 (en) Treatment of medium-chain acyl-coa dehydrogenase deficiency
EP3060246A4 (en) Compositions and methods for prophylaxis and therapy of clostridium difficile infection
UA115583C2 (en) Azetidinyloxyphenylpyrrolidine compounds
AU2014205587A8 (en) SHIP1 modulators and methods related thereto
AU2015292632B2 (en) Aldosterone synthase inhibitors
EP3082845A4 (en) Methods and compositions for treatment of peripheral neuropathies
WO2012022496A3 (en) Method for killing tumor stem cells
IN2014CN02315A (en)

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 26.10.2012.)

122 Ep: pct application non-entry in european phase

Ref document number: 11733319

Country of ref document: EP

Kind code of ref document: A2